SymBio Pharmaceuticals

2023.05.29: IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial
2023.05.10: Onconova Therapeutics announces presentation of an overview of its investigator-sponsored clinical program evaluating rigosertib monotherapy in RDEB-associated SCC at the ISID International Epidermolysis Bullosa Symposium in Osaka
2023.04.27: Analyst Report[Flash report] (Shared Research)
2023.04.27: Summary of Consolidated Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
2023.04.24: SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease
2023.04.14: Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Directors
2023.04.14: Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Employees
2023.03.24: Notice of Shareholder Voting Results for the 18th Annual General Meeting of Shareholders
2023.03.23: Notice of Appointments to the Board of Directors and substitute member of the Audit & Supervisory Committee, and Appointments of Corporate Officers
2023.03.23: Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2023.03.23: Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2023.03.22: Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)
2023.03.01: Information on Shareholders' Meeting: Updated the Page
2023.02.22: Notification of Amendment to the Articles of Incorporation
2023.02.09: Analyst Report[Flash report] (Shared Research)
2023.02.09: Summary of Financial Statements for the Fiscal Year Ended December 31, 2022 [Japanese GAAP] (Consolidated)
2023.02.09: Notice concerning non-operating expenses
2023.01.23: Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
2023.01.16: Analyst Report[Follow-up Report] (Fair Research)
2022.12.26: SymBio files lawsuit against Pfizer Japan Inc. for infringement of TREAKISYM patents
2022.12.19: SymBio enters into Sponsored Research Agreement for non-clinical study to verify the effectiveness of brincidofovir in a virus-infected brain tissue model
2022.12.16: SymBio files lawsuit for infringement of TREAKISYM patents
2022.12.14: SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV in Australia
2022.12.13: Presentation on the Anti-lymphoma Activity of Brincidofovir at the 64th ASH Annual Meeting
2022.12.12: Analyst Report[Full report] (Shared Research)
2022.11.24: SymBio enters into Material Transfer Agreement with Penn State College of Medicine for a non-clinical study to evaluate the efficacy of brincidofovir in a polyomavirus model
2022.11.08: Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
2022.11.08: Revision to Earnings Forecast for FY 2022
2022.09.27: Chimerix announces closing of brincidofovir sale to Emergent BioSolutions
2022.08.31: Notice of Appointment of Corporate Officer
2022.08.22: SymBio submits clinical trial notification to TGA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation in Australia
2022.08.09: The National Institute of Neurological Disorders and Stroke and SymBio Pharmaceuticals Limited will collaborate to evaluate the potential antiviral activity of brincidofovir (BCV) against Epstein Barr virus (EBV)
2022.08.05: Analyst Report[Update report] (Shared Research)
2022.08.04: Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
2022.08.04: Revision to Earnings Forecast for FY 2022
2022.07.11: SymBio announces the publication of the results of its Phase I/II clinical study of the rapid infusion (RI) administration of TREAKISYM liquid formulation
2022.06.16: Notice of Resignation of Director
2022.06.14: SymBio submits clinical trial notification to PMDA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation
2022.06.13: SymBio announces status of market adoption of the 10-minute Rapid Infusion (RI) administration of the TREAKISYM Liquid Formulation
2022.06.08: Analyst Report[Basic Report] (Fair Research)
2022.06.03: Analyst Report[Full report] (Shared Research)
2022.06.01: Completion of Payment for the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
2022.05.24: Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
2022.05.18: Chimerix announces sale of brincidofovir to Emergent BioSolutions
2022.05.16: Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
2022.05.11: Summary of Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
2022.04.22: Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
2022.04.22: Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
2022.04.01: Joint research agreement with the National Cancer Center on rare cancers
2022.03.31: Notice of Renewal of Syndicated Loan Agreement
2022.03.30: Notice of Shareholder Voting Results for the 17th Annual General Meeting of Shareholders
2022.03.29: Notice of Appointments to the Board of Directors and the Audit & Supervisory Committee, and Appointments of Corporate Officers
2022.03.29: Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2022.03.29: Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2022.03.25: Analyst Report[Full report] (Shared Research)
2022.03.09: Information on Shareholders' Meeting: Updated the Page
2022.03.08: SymBio announces publication the final results of its phase 3 clinical trial of TREAKISYM in r/r DLBCL
2022.03.07: SymBio announces initiation of non-clinical study of brincidofovir IV for brain tumors in collaboration with Brown University, USA
2022.02.28: SymBio receives approval of TREAKISYM Liquid Formulation Rapid Infusion (RI) administration
2022.02.25: Response to marketing approvals of generic products
2022.02.24: Notification of Amendments to the Articles of Incorporation
2022.02.24: Notice regarding the transition to a company with an audit and supervisory committee and nomination of directors
2022.02.24: SymBio announces results of a collaborative study with the National Institute of Infectious Diseases on adenoviruses and the antiviral agent brincidofovir
2022.02.10: Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated)
2022.02.10: Notice concerning non-operating expenses
2022.02.10: Notice regarding difference between earnings forecast and the actual results for the fiscal year ended December 31, 2021
2022.01.31: Initiation of a phase 2 clinical trial of bendamustine and rituximab combination therapy followed by autologous hematopoietic stem cell transplantation in patients with relapsed or refractory diffuse large B-cell lymphoma
2022.01.18: SymBio submits clinical trial application to MHRA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for treatment of pediatric adenovirus infection
2022.01.06: Joint research agreement to establish a Social Collaboration Course, Molecular Oncology, with the University of Tokyo
2021.12.24: Notice of Appointment of Executive Vice President, Corporate Officer and COO
2021.12.20: Notice of Appointment of Corporate Officer
2021.12.06: Analyst Report[Follow-up Report] (Fair Research)
2021.12.03: Analyst Report[Full report] (Shared Research)
2021.11.24: SymBio receives approval of shelf-life extension forTREAKISYM ready-to-dilute (RTD) liquid formulation
2021.11.11: Analyst Report[Update report] (Shared Research)
2021.11.11: Summary of Financial Statements for the Third Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
2021.11.11: Notice Concerning Non-operating Expenses